Agenus (AGEN) Tanks on Colorectal Cancer Study Interim Data

Shares of Agenus Inc. (AGEN) plunged 58.8% on Jul 18 after the company announced the outcome of its end-of-phase II (EOP2) meeting with the FDA regarding the accelerated development of its immunotherapy combination botensilimab (BOT) and balstilimab (BAL).The BOT/BAL combination is being studied for the treatment of adult patients with relapsed/refractory microsatellite stable colorectal cancer (r/r MSS CRC) with no active liver metastases.The FDA discouraged the accelerated approval pathway for the BOT/BAL ...